Durham, NC (PRWEB) January 03, 2012
STEM CELLS, the premier peer-reviewed journal in the field of stem cells and regenerative medicine, promoted Professor Jan A. Nolta to Editor.
Nolta, one of the nation’s leading researchers in regenerative medicine, directs the University of California-Davis “Institute for Regenerative Cures” that is supported by the California Institute for Regenerative Medicine (CIRM). In addition to conducting groundbreaking research in human stem cells, she directs the university’s stem cell program that includes more 150 scientists and clinicians from the University of California (UC)-Davis and -Sacramento campuses.
“There has never been such an exciting time to be a scientist in the field of stem cell research,” said Nolta. “The tools and techniques that we now have are unprecedented, and allow us to probe the biology of stem cells in entirely new ways. I look for¬ward to tackling my new role with both a zeal and deep respect for the global scientific community.”
Nolta joined UC Davis in 2006 after serving for four years as scientific director of the cell and gene therapy Good Manufacturing Practice (GMP) facility at Washington University School of Medicine, St. Louis. Her translational research has focused on developing improved stem cell therapies for treating neurodegenerative diseases including Huntington's and Parkinson's disease, immunodeficiencies, lysosomal storage diseases and peripheral vascular disease.
Nolta has had more than 20 years experience in the stem cell field. She has published more than 100 manuscripts in the field of regenerative medicine and has authored 25 book chapters and numerous invited papers. She was author and editor of the book, “Genetic Engineering of Mesenchymal Stem Cells.” She has served on more than 75 National Institutes of Health grant review panels and has been editor and editorial board member on six scientific journals.
Nolta also serves as the scientific director of the UC-Davis/CIRM Good Manufacturing Practice (GMP) facility located within the Institute for Regenerative Cures; it is one of the largest academic GMP laboratories in the nation. Her ultimate goal in studying stem cell biology is to help teams develop more effective therapies for patients who currently have few options.
Having served STEM CELLS as an associate editor she takes up her editor’s responsibilities as the Journal celebrates its 30th anniversary. STEM CELLS, founded in 1893, is the first peer-reviewed journal devoted to stem cell research. Its founding publisher, AlphaMed Press, is celebrating its 30th Anniversary with the launch of STEM CELLS’ sister journal, STEM CELLS TRANSLATIONAL MEDICINE, edited by Professor Anthony Atala.
Nolta also saluted departing editor Miodrag Stojković, saying, “We are grateful to Professor Stojković for his service to the Journal. He was a consummate editor devoted to the publica¬tion of the most important scientific advances in this fast-paced and promising research arena.”
About the Journal:
STEM CELLS, a peer reviewed journal published monthly, provides a forum for prompt publication of original investigative papers and concise reviews. The journal covers all aspects of stem cells: embryonic stem cells/induced pluripotent stem cells; tissue-specific stem cells; cancer stem cells; the stem cell niche; stem cell epigenetics, genomics and proteomics; and translational and clinical research.
For more information, please visit: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1549-4918
STEM CELLS is co-published by AlphaMed Press and Wiley-Blackwell.
About AlphaMed Press: Established in 1983, AlphaMed Press with offices in Durham, NC, San Francisco, CA and Belfast, UK, publishes three premier peer-reviewed journals with globally recognized editorial boards dedicated to advancing knowledge and education in their focused disciplines. STEM CELLS® (http://www.StemCells.com), celebrating its 30th anniversary in 2012, is the world's first journal devoted to this fast paced field of research. THE ONCOLOGIST® (http://www.TheOncologist.com), entering its 17th year, is devoted to community and hospital-based physicians entrusted with cancer patient care. STEM CELLS Translational Medicine will debut January 2012 (http://www.StemCellsTM.com) with the mission to hasten the clinical applications of stem cell research.
About Wiley-Blackwell: Wiley-Blackwell is the international scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, with strengths in every major academic and professional field and partnerships with many of the world’s leading societies. Wiley-Blackwell publishes nearly 1,500 peer-reviewed journals and 1,500+ new books annually in print and online, as well as databases, major reference works and laboratory protocols. For more information, please visit http://www.wileyblackwell.com or our new online platform, Wiley Online Library (wileyonlinelibrary.com), one of the world’s most extensive multidisciplinary collections of online resources, covering life, health, social and physical sciences, and humanities.